Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699253 | Clinical Oncology | 2009 | 9 Pages |
Abstract
There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R.M. Eager, C.C. Cunningham, N. Senzer, D.A. Richards, R.N. Raju, B. Jones, M. Uprichard, J. Nemunaitis,